HUTCHMED (China) Limited (HCM)
NEUTRALFundamental
42
मूल्य
$12.24
मार्केट कैप
$2.12B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$109M
अंतिम प्रकाशित तिमाही तक के पिछले 12 महीने — प्रति शेयर मेट्रिक्स से अनुमानित
शुद्ध आय
$91M
अंतिम प्रकाशित तिमाही तक के पिछले 12 महीने — प्रति शेयर मेट्रिक्स से अनुमानित
Free Cash Flow
$-19M
कुल इक्विटी
$1.26B
कुल देनदारियाँ
$95M
Current Ratio
5.64
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$8.56
वर्तमान मूल्य
$12.24
Margin of Safety
-43.0%
Fair Value सीमा
$5.56 - $11.56
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
23.26
ROE
1.5%
P/B Ratio
8.58
P/FCF
-
Gross Margin
38.7%
ROIC
0.1%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
0.1%
WACC
10.4%
ROIC − WACC
-10.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (8)
- Gross Margin 38.7%
- Debt/Equity ratio
- Current Ratio
- ROE 37.0%
- Revenue Growth 5Y 19.2%
- Analyst Consensus 85% Buy
- Earnings Surprise avg 95.6%
- Net Margin Trend 83.3% vs 6.0%
फेल (9)
- Price CAGR -0.72%
- ROIC 0.1%
- P/B Ratio 8.58
- Operating Margin -7.1%
- Positive Free Cash Flow
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Quality (OCF/NI) 0.04
- Piotroski F-Score 1/9
अनुपलब्ध (10)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Chig Fung Cheng BEc, CA | Acting CEO, CFO & Executive Director | 58 |
| Dr. Wei-Guo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Executive Director (Leave of Absence) | 66 |
| Ms. Yiling Cui | Executive VP & Head of Operations | - |
| Dr. Xinhui Hu Ph.D. | Executive Vice President & Chief Technical Officer | 52 |
| Mr. David Ng | Head of Investor Relations & Capital Strategies | - |
| Mr. Charles George Rupert Nixon | Group General Counsel | 55 |
| Mr. Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management & Communications | 48 |
| Ms. Selina Zhang | Senior Vice President of Global Human Resources | - |
| Dr. Qingmei Wang Ph.D. | Executive Vice President of Business Development & Strategic Alliances | 62 |
| Dr. Thomas Fu | Senior Vice President of Global Quality | - |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for HCM, sourced from Markets Gazette.